Q1 Earnings Forecast for Immunome Issued By Leerink Partnrs

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Immunome in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings of ($0.94) per share for the quarter. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Leerink Partnrs also issued estimates for Immunome's Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($4.06) EPS, FY2026 earnings at ($4.17) EPS and FY2027 earnings at ($3.80) EPS.

Other equities research analysts have also recently issued research reports about the stock. Wedbush reissued an "outperform" rating and set a $33.00 target price on shares of Immunome in a report on Monday, January 13th. Piper Sandler lowered their target price on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. Finally, Stephens initiated coverage on shares of Immunome in a report on Friday, November 8th. They set an "overweight" rating and a $30.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $28.60.

Immunome Trading Up 0.3 %

Shares of NASDAQ:IMNM traded up $0.03 during mid-day trading on Monday, reaching $10.43. The company had a trading volume of 439,000 shares, compared to its average volume of 1,039,176. The company's 50-day moving average price is $10.98 and its 200-day moving average price is $12.49. Immunome has a one year low of $8.97 and a one year high of $30.96. The firm has a market cap of $832.11 million, a price-to-earnings ratio of -1.29 and a beta of 1.90.

Institutional Trading of Immunome

Several hedge funds have recently added to or reduced their stakes in IMNM. JPMorgan Chase & Co. lifted its stake in Immunome by 2,540.4% in the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock worth $6,888,000 after purchasing an additional 624,045 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock valued at $50,971,000 after acquiring an additional 324,614 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Immunome by 2,696.5% during the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company's stock valued at $3,356,000 after acquiring an additional 304,700 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Immunome by 217.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company's stock valued at $6,469,000 after acquiring an additional 302,916 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in shares of Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock valued at $10,684,000 after acquiring an additional 237,497 shares during the last quarter. 44.58% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Immunome news, CTO Philip Tsai purchased 21,000 shares of the stock in a transaction on Thursday, November 21st. The stock was acquired at an average cost of $9.43 per share, with a total value of $198,030.00. Following the completion of the purchase, the chief technology officer now directly owns 21,000 shares of the company's stock, valued at approximately $198,030. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Clay B. Siegall purchased 150,000 shares of the stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the purchase, the chief executive officer now directly owns 669,636 shares of the company's stock, valued at $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 252,862 shares of company stock worth $2,140,545. Corporate insiders own 8.60% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.